These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20451370)

  • 1. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
    Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.
    Hajji N; Wallenborg K; Vlachos P; Nyman U; Hermanson O; Joseph B
    Oncogene; 2008 May; 27(22):3134-44. PubMed ID: 18071312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
    Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
    Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
    Arúajo AM; Mendez JC; Coelho AL; Sousa B; Barata F; Figueiredo A; Amaro T; Azevedo I; Soares M
    Cancer Invest; 2009 May; 27(4):391-6. PubMed ID: 19266367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
    Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
    Tatebe H; Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Tsurumi H; Moriwaki H
    Cancer Lett; 2009 Nov; 285(2):210-7. PubMed ID: 19520494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
    Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
    Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
    Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
    Gavrilov V; Lavrenkov K; Ariad S; Shany S
    Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
    Bartling B; Lewensohn R; Zhivotovsky B
    Exp Cell Res; 2004 Aug; 298(1):83-95. PubMed ID: 15242764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
    Gao D; Xia Q; Lv J; Zhang H
    Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
    Chen Q; Ouyang DY; Geng M; Xu LH; Zhang YT; Wang FP; He XH
    J Immunotoxicol; 2011; 8(3):210-8. PubMed ID: 21457087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
    Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
    Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.